CIRM - California Institute for Regenerative Medicine
09/10/2024 | News release | Distributed by Public on 09/10/2024 10:53
CIRM awards $26 million to boost clinical trials for cancer, heart, and rare diseases
[Link]
The California Institute for Regenerative Medicine (CIRM) is proud to announce the allocation of $26 million to support clinical research targeting a range of cancers, heart conditions, and rare diseases. This significant funding underscores CIRM's commitment to advancing innovative stem cell and gene therapy-based treatments through all stages of clinical trial development.
This latest round of awards will support five projects within CIRM's Clinical program, which aims to provide critical funding for eligible projects at various stages of their development. These new awards bring the total number of CIRM-funded clinical trials to 108, highlighting our ongoing dedication to fostering groundbreaking research and transformative therapies.
The recipients of CIRM's Clinical program funding this month include:
| Grant Title and Application Number | Principal Investigator/Institution | Award Amount |
| CLIN1-14792: Superior forward-oriented b-globin vector for treating Sickle Cell Disease | Abedi, Mehrdad - UC Davis | $4,619,455 |
| CLIN1-14825: Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) | Weiss, Yael - Mahzi Therapeutics | $4,000,000 |
| CLIN1-16244: Novel Gene Therapy Targeting Multiple Pathological Drivers of Desmoplakin Associated Arrhythmogenic Cardiomyopathy | Ascheim, Deborah D. - Rejuvenate Bio | $4,000,000 |
| CLIN2-15218: A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV Gene Therapy in Male Patients with Danon Disease | Schwartz, Jonathan - Rocket Pharmaceuticals, Inc. | $5,808,735 |
| CLIN2-16156: Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies | Emery, Rochelle - Senti Bio | $8,000,000 |
These projects represent a crucial step in improving patient outcomes and offering new hope for individuals affected by these severe health challenges.
CIRM remains committed to supporting the most promising regenerative medicine research, intending to accelerate the development of treatments and cures. We are excited to see the progress that will be made possible through these new grants and look forward to their positive impact on patients' lives.